IL-22 inhibits ferroptosis and attenuates ischemia-reperfusion-induced acute kidney injury: Association with activation of the P62-Keap1-Nrf2 signaling pathway
PLOS One · 2026
DOI: 10.1371/journal.pone.0342335 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Lin Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Ferroptosis, Interleukins, Reperfusion Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute kidney injury (AKI) remains a major clinical challenge due to its high morbidity and mortality, with ischemia-reperfusion injury (IRI) as one of its primary causes. Severe IRI-associated AKI (IRI-AKI) can progress to irreversible renal failure, yet no effective therapies are currently available. Ferroptosis, an iron-dependent regulated cell death, has recently been implicated in the pathogenesis of IRI-AKI. Moreover, IL-22 may alleviate AKI by modulating the ferroptosis process through regulation of the P62-Keap1-Nrf2 signaling axis. In this study, we examined the protective role of the immune cytokine interleukin-22 (IL-22) in IRI-AKI and its mechanistic association with ferroptosis. Using a murine IRI model and an HK-2 cell hypoxia/reoxygenation system, we systematically assessed the impact of IL-22 treatment. IL-22 administration significantly enhanced renal function, reduced histological injury, and limited both reactive oxygen species accumulation and ferroptotic cell death. Further mechanistic studies demonstrated that IL-22 suppresses ferroptosis in vitro through an Nrf2-dependent mechanism and is associated with activation of the P62-Keap1-Nrf2 signaling pathway. These findings offer experimental evidence supporting IL-22 as a potential therapy for IRI-AKI and highlight ferroptosis modulation as a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.
- Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.
ORCID-Profile: Congjuan Luo
Zitieren
APA
Zhang, L., Luo, F., Chai, Y., Sun, L., Wang, X., Yin, L., & Luo, C. (2026). IL-22 inhibits ferroptosis and attenuates ischemia-reperfusion-induced acute kidney injury: Association with activation of the P62-Keap1-Nrf2 signaling pathway. PLOS One. https://doi.org/10.1371/journal.pone.0342335
Vancouver
Zhang L, Luo F, Chai Y, Sun L, Wang X, Yin L, et al. IL-22 inhibits ferroptosis and attenuates ischemia-reperfusion-induced acute kidney injury: Association with activation of the P62-Keap1-Nrf2 signaling pathway. PLOS One. 2026. doi:10.1371/journal.pone.0342335
BibTeX
@article{Zhang2026,
author = {Zhang, Lin and Luo, Feng and Chai, Yalin and Sun, Lijie and Wang, Xuan and Yin, Le and Luo, Congjuan},
title = {IL-22 inhibits ferroptosis and attenuates ischemia-reperfusion-induced acute kidney injury: Association with activation of the P62-Keap1-Nrf2 signaling pathway},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342335}
}
EUVIMED